Pharmacogenomics and Personalized Medicine: A Revolution in Drug Therapy

The field of pharmacogenomics, which examines how an individual's genetic makeup influences their response to medications, is at the forefront of a paradigm shift in modern healthcare. As part of the broader movement toward personalized medicine, pharmacogenomics enables the development and implementation of tailored therapeutic strategies aimed at optimizing efficacy and minimizing adverse drug reactions (ADRs). Traditional "one-size-fits-all" drug therapies often fail to account for interindividual variability in drug metabolism, efficacy, and toxicity factors now known to be significantly influenced by genetic differences. This review explores the scientific foundations, clinical applications, and ongoing challenges of pharmacogenomics in contemporary medical practice. We discuss the most significant pharmacogenetic markers, including polymorphisms in cytochrome P450 enzymes (such as CYP2D6, CYP2C19, and CYP2C9), drug transporter genes (e.g., SLCO1B1), and genes involved in drug targets and immune responses (e.g., HLA-B, VKORC1). Applications of pharmacogenomics are particularly advanced in oncology, cardiology, psychiatry, and infectious diseases, where genetic testing informs the use of drugs like warfarin, clopidogrel, trastuzumab, and abacavir. The integration of genetic data into clinical workflows holds the promise of not only enhancing therapeutic outcomes but also reducing healthcare costs associated with ineffective treatment and adverse effects. Despite these benefits, widespread adoption of pharmacogenomics is hindered by several challenges, including limited clinician awareness, high testing costs, insufficient regulatory frameworks, and ethical concerns related to privacy and data security. Emerging technologies such as next-generation sequencing (NGS), electronic health record (EHR) integration, and artificial intelligence (AI)-driven decision support are expected to accelerate clinical implementation. Ultimately, pharmacogenomics represents a cornerstone of precision medicine and a revolutionary step toward more individualized, effective, and safe drug therapy. This review highlights current evidence, future prospects, and the systemic changes needed to fully realize the potential of pharmacogenomics in routine clinical practice.

Institutions

Publication Details

Journal
Research Journal of Pharmacology and Pharmacodynamics
Published
2025-10-11
DOI
https://doi.org/10.52711/2321-5836.2025.00048
Primary Topic
Pharmacogenetics and Drug Metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pharmacogenomics and Personalized Medicine: A Revolution in Drug Therapy

Research Journal of Pharmacology and Pharmacodynamics
Pharmacogenetics and Drug Metabolism
article

Pharmacogenomics and Personalized Medicine: A Revolution in Drug Therapy

article en

Abstract

The field of pharmacogenomics, which examines how an individual's genetic makeup influences their response to medications, is at the forefront of a paradigm shift in modern healthcare. As part of the broader movement toward personalized medicine, pharmacogenomics enables the development and implementation of tailored therapeutic strategies aimed at optimizing efficacy and minimizing adverse drug reactions (ADRs). Traditional "one-size-fits-all" drug therapies often fail to account for interindividual variability in drug metabolism, efficacy, and toxicity factors now known to be significantly influenced by genetic differences. This review explores the scientific foundations, clinical applications, and ongoing challenges of pharmacogenomics in contemporary medical practice. We discuss the most significant pharmacogenetic markers, including polymorphisms in cytochrome P450 enzymes (such as CYP2D6, CYP2C19, and CYP2C9), drug transporter genes (e.g., SLCO1B1), and genes involved in drug targets and immune responses (e.g., HLA-B, VKORC1). Applications of pharmacogenomics are particularly advanced in oncology, cardiology, psychiatry, and infectious diseases, where genetic testing informs the use of drugs like warfarin, clopidogrel, trastuzumab, and abacavir. The integration of genetic data into clinical workflows holds the promise of not only enhancing therapeutic outcomes but also reducing healthcare costs associated with ineffective treatment and adverse effects. Despite these benefits, widespread adoption of pharmacogenomics is hindered by several challenges, including limited clinician awareness, high testing costs, insufficient regulatory frameworks, and ethical concerns related to privacy and data security. Emerging technologies such as next-generation sequencing (NGS), electronic health record (EHR) integration, and artificial intelligence (AI)-driven decision support are expected to accelerate clinical implementation. Ultimately, pharmacogenomics represents a cornerstone of precision medicine and a revolutionary step toward more individualized, effective, and safe drug therapy. This review highlights current evidence, future prospects, and the systemic changes needed to fully realize the potential of pharmacogenomics in routine clinical practice.

Research Journal of Pharmacology and Pharmacodynamics
American Association of Colleges of Pharmacy (US)
Openalex Percentile: Top 38%
Pharmacogenetics and Drug Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.